NextCell Pharma publishes Interim Report 3 2021/2022

July 28, 2022

NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 3 for the period September 1, 2021 – May 31, 2022 The report is available on the company’s website:
https://www.nextcellpharma.com/en/investors#financial-report.NextCells share is traded on Nasdaq First North Growth Market under the ticker"NXTCL". The amount in brackets refers to the corresponding period in the previous year.

Third quarter (2022-03-01 until 2022-05-31)

● Operating income amounted to 1 636 (906) TSEK.

● Operating result amounted to -9 307(-6 457)TSEK.

● Earnings per share* amounted to -0,27 (-0,19)SEK.

● Cash and bank amounted to 107 054 (150 754)TSEK.

● Solidity** amounted to 93,5 (96,9) %.

First nine months (2021-09-01 till 2022-05-31)

● Operating income amounted to 4 824 (3 074) TSEK.

● Operating result amounted to -25 991 (-20 079)TSEK.

● Earnings per share* amounted to -0,22 (-0,69)SEK.
‍

Earnings per share: Profit for the period divided by average number of shares. Average number of shares for the second quarter 2021/2022: 34,379,523(34,056,943) shares. Average number of shares for the first nine months2021/2022: 34,379,523 (29,074,754) shares. Number of shares in NextCell as of May31, 2022: 34,379,523 (34,379,523) shares.

**Solidity: Own capital's share of the sheet total

Significant events in the third quarter

● NextCell announced in early April that the stemcell bank Cellaviva has disclosed stem cells from umbilical cord blood to Rigshospitalet, Denmark's premier hospital. A sibling of the child whose umbilical cord blood was saved in Cellaviva's biobank, suffers from a serious blood disorder to be treated with stem cells at the Hematology Department at Rigshospitalet.

● NextCell announced in early April that all three children in the age group 12-18 years have been treated with ProTrans. Professor Per-Ola Carlsson and the study team are now moving forward with younger patients, three children in the age group 7-11 years
‍
● NextCell announced at the end of April that it is participating in a conference for world-leading cell therapies, the International Society for Cell and Gene Therapy 2022, in San Francisco and is represented by Mathias Svahn, CEO. Dr Svahn is a member of the Business Development and Finance Committee of ISCT.

● NextCell announced at the end of May that the company is presenting the ongoing clinical trial program with the drug candidate ProTrans lead cell therapy at the Advanced Therapies Congress in London on May 24-25.

● NextCell announced at the end of May that the European Patent Office(EPO) had issued an advance grant notice of the patent entitled "Allogeneic Composition" (publication numberEP3752598). The patent describes the method of manufacturing the drug candidate ProTrans and where the selection algorithm for selecting optimal cells and donors is the core. Patent protection is valid up to and i 2039.

Significant events after the reporting period

● NextCell announced in early June that all six children in the first part of the study with ProTrans. Patients will be monitored during the summer after which the safety of the treatment will be evaluated by an independent safety committee.

‍
This disclosure contains information that NextCell Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014) and the Swedish Securities Markets Act (2007:528). The information was submitted for publication, through the agency of the contact person, on 28-07-2022 07:30 CET.

For more information about NextCell Pharma AB, please contact:

Mathias Svahn, CEO

Patrik Fagerholm, CFO

Tel: 08-735 5595

E-mail: info@nextcellpharma.com

Websites:
www.nextcellpharma.com
www.cellaviva.se
www.cellaviva.dk

LinkedIn: https://www.linkedin.com/company/15255207/

Twitter: https://twitter.com/NextCellPharma

Instagram: https://www.instagram.com/cellaviva/

‍

About NextCell Pharma AB

NextCell is a phase II cell therapy company with the drug candidate ProTrans for the treatment of type 1 diabetes. The focus is to take ProTrans to market approval via a Phase III study. ProTrans is in addition to diabetes, used in two clinical trials for Covid-19, in Örebro and Montreal (Canada). The company is in the processes of establishing its own GMP facility for production of ProTrans. The GMP facility is expected to be ready for production of smaller quantities of ProTrans in 2023. NextCell furthermore owns 8,5% in FamicordTX, a CAR-T start-up in oncology and 100 % of Cellaviva, Scandinavia's largest stem cell bank for family saving stem cells from umbilical cord blood and umbilical cord tissue with permission from the Swedish Health and Social Care Inspectorate (IVO).

‍

Download attachment Read full press release on Cision (external link)

2021-10-26

NextCell increases market potential and reduces the risk of ProTrans' clinical trial program in type 1 diabetes

NextCell Pharma AB ("NextCell" or the "Company") updates the strategy for the clinical trial program in type 1 diabetes with ProTrans. The aim is to increase potential while reducing the risk. This can be achieved by waiting for preliminary safetydata from the approved ProTrans-Young pediatric trial before submitting the application for ProTrans-3, scheduled for H2 2022. Advantages of the updated strategy for future application for marketing approval are: · Lower age limit for treatment is desirable and could potentially double the intitial market · Increased long term data from

Read more Read more

2021-10-06

NextCell invited speaker at the Advanced Therapy Congress in London

Today, NextCell Pharma AB’s CEO, Dr. Mathias Svahn, is presenting clinical data from the ProTrans-1 and ProTrans-2 diabetes studies. Ranked as one of Europe's most important events in the field of advanced therapies, the ExCel event brings together leading players in the pharmaceutical industry to provide information on the latest technologies attracting more than 2,000 visitors. The scope of the summit is to explore, define and tackle the challenges of, and patient access to ATMPs (Advanced Therapy Medicinal Products), as the field moves into an exciting 2022. NextCell has developed an

Read more Read more

2021-09-09

All patients in the low-dose group treated with ProTrans

NextCell Pharma AB ("NextCell" or the "Company") announces that three patients with Covid-19 have now been treated with ProTrans in the Swedish study ProTrans19+SE conducted at Örebro University Hospital. As a result, all patients in the low-dose cohort are now treated. The full title of the study is: "Treatment of Respiratory Complications Associated with COVID-19 Infection with Wharton's Jelly (WJ) -Umbilical Cord (UC) Mesenchymal Stromal Cells (ProTrans®): An Open Phase IB Clinical Trial", (EudraCT 2020-002078-29). NextCell sponsors the study, which will include a total of nine patients

Read more Read more

2021-08-17

NextCell files patent application for treatment of COVID-19 with ProTrans

NextCell Pharma AB ("NextCell" or the "Company”) announces that a patent application has been filed for the treatment of Sars-CoV-2 mediated severe pneumonia with ProTrans. NextCell increases the IP protection for the drug candidate ProTrans for the treatment of autoimmune diseases and inflammatory conditions. The latest patent application has is entitled; "Allogeneic Composition for Treatment off Covid-19". By using the possibility of priority from a previous application, the COVID-19 application has a priori day of August 14, 2020, i.e. dated 1 year back in time. NextCell has filed a

Read more Read more

2021-07-30

NextCell Pharma publishes Interim Report 3 2020/2021

NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 2 for the period September 1, 2020 - February 28, 2021 The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year. Third quarter (2020-03-01 until 2021-05-31) · Operating income amounted to SEK 905 750 (750 512). · Operating result amounted to SEK -6 457 514 (-4 833 332). · Earnings

Read more Read more

2021-06-22

NextCell enters CAR-T joint venture

NextCell Pharma AB (“NextCell”) today announces a joint venture together with their long-term collaborator and contract manufacture organisation, Polski Bank Komórek Macierzystych (PBKM, FamiCord Group). NextCell has acquired ~10 % of shares in the newly started company FamiCordTx through a directed equity issue, raising the capital with 0,5 MEuro in cash. FamiCordTx has exclusively licensed a patent pending CAR-T technology and the tech transfer is completed, and the production of CAR-T cell therapy is awaiting ATMP manufacturing approval before production of CAR-T for clinical trial use can

Read more Read more

2021-06-17

Advisory meeting with the European Medicines Agency

NextCell Pharma AB (“NextCell” or “the Company”) announces that a scientific advisory meeting with the European Medicines Agency (EMA) has been held regarding ProTrans and the path forward to a possible market approval. The focus was the design of the phase III study ProTrans-3, which NextCell intends to submit an application for later this year.

Read more Read more

2021-06-10

COVID-19 patient treated with ProTrans

NextCell Pharma AB (“NextCell” or “the Company”) announces that the first patient with severe pneumonia, as a result of COVID-19 infection, has now been treated with ProTrans. The patient was hospitalized at Örebro University Hospital, where the phase 1b study ProTrans19+SE is in progress led by Principal Investigator Associate Professor Josefin Sundh. NextCell's drug candidate, ProTrans, is an immune- balancing cell therapy for the treatment of autoimmune diseases and inflammatory conditions. Patients with severe pneumonia as a result of by SARS-CoV-2 infection are at risk of rapid

Read more Read more